{"id":62685,"date":"2026-04-27T00:51:21","date_gmt":"2026-04-26T22:51:21","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2026\/04\/27\/targeting-the-il-6-il-17-amplifier-loop-in-fibroblasts-insights-from-chronic-antibody-mediated-rejection-in-kidney-transplant-patients\/"},"modified":"2026-04-27T00:51:21","modified_gmt":"2026-04-26T22:51:21","slug":"targeting-the-il-6-il-17-amplifier-loop-in-fibroblasts-insights-from-chronic-antibody-mediated-rejection-in-kidney-transplant-patients","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2026\/04\/27\/targeting-the-il-6-il-17-amplifier-loop-in-fibroblasts-insights-from-chronic-antibody-mediated-rejection-in-kidney-transplant-patients\/","title":{"rendered":"Targeting the IL-6\/IL-17 amplifier loop in fibroblasts: insights from chronic antibody-mediated rejection in kidney transplant patients"},"content":{"rendered":"<div>\n<p><b>J Immunol<\/b>. 2026 Apr 15;215(4):vkag057. doi: 10.1093\/jimmun\/vkag057.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Chronic antibody-mediated kidney rejection (CABMR) is a major cause of chronic allograft injury. Fibroblasts have been implicated in mediating this injury through activation of the IL-6 amplifier loop (IL-6 + IL-17), driven by the NF-\u03baB and STAT3 signaling pathways. This study investigated the activation of the IL-6 amplifier loop in fibroblasts isolated from renal biopsies of patients with CABMR and evaluated the effects of IL-6 and IL-17 inhibition. Fibroblasts were cultured from 6 CABMR patient biopsy samples and treated with anti-IL-6 (100 ng\/mL) and anti-IL-17 (0.75 \u00b5g\/mL), both before and after stimulation with IL-6\/soluble IL-6 receptor (sIL-6R) (20 ng\/\u00b5L), IL-17 (50 ng\/\u00b5L), or a combination. IL-6, CCL2, and CCL20 levels were measured in the culture supernatants by ELISA. The mRNA expression of IL-6, CCL2, CCL20, and SOCS3 was assessed using qPCR, and protein expression was evaluated by western blot for phosphorylated STAT3 and NF-\u03baB p65. Synergistic activation of IL-6\/sIL-6R and IL-17 significantly increased IL-6, CCL20, and MCP-1 production, whereas SOCS3 expression was downregulated. Phosphorylation of NF-\u03baB and STAT3 was also elevated. The combined inhibition of IL-6 and IL-17 effectively reduced IL-6, MCP-1, and CCL20 levels, restored SOCS3 expression, and attenuated NF-\u03baB and STAT3 phosphorylation. These findings highlight the role of the IL-6 amplifier loop as a potential therapeutic target in CABMR.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42035495\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=2985117R&amp;ff=20260426185120&amp;v=2.19.0.post6+133c1fe\">42035495<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1093\/jimmun\/vkag057\">10.1093\/jimmun\/vkag057<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>J Immunol. 2026 Apr 15;215(4):vkag057. doi: 10.1093\/jimmun\/vkag057. ABSTRACT Chronic antibody-mediated kidney rejection (CABMR) is a major cause of chronic allograft injury. Fibroblasts have been implicated in mediating this injury through activation of the IL-6 amplifier loop (IL-6 + IL-17), driven by the NF-\u03baB and STAT3 signaling pathways. This study investigated the activation of the IL-6 &#8230; <a title=\"Targeting the IL-6\/IL-17 amplifier loop in fibroblasts: insights from chronic antibody-mediated rejection in kidney transplant patients\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/27\/targeting-the-il-6-il-17-amplifier-loop-in-fibroblasts-insights-from-chronic-antibody-mediated-rejection-in-kidney-transplant-patients\/\" aria-label=\"Read more about Targeting the IL-6\/IL-17 amplifier loop in fibroblasts: insights from chronic antibody-mediated rejection in kidney transplant patients\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42,71],"tags":[],"class_list":["post-62685","post","type-post","status-publish","format-standard","hentry","category-publicaciones","category-the-journal-of-immunology"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/62685","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=62685"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/62685\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=62685"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=62685"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=62685"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}